These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 12716445)

  • 1. COX-2: Where are we in 2003? - Be strong and resolute: continue to use COX-2 selective inhibitors at recommended dosages in appropriate patients.
    Hochberg MC
    Arthritis Res Ther; 2003; 5(1):28-31. PubMed ID: 12716445
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study.
    Silverstein FE; Faich G; Goldstein JL; Simon LS; Pincus T; Whelton A; Makuch R; Eisen G; Agrawal NM; Stenson WF; Burr AM; Zhao WW; Kent JD; Lefkowith JB; Verburg KM; Geis GS
    JAMA; 2000 Sep; 284(10):1247-55. PubMed ID: 10979111
    [TBL] [Abstract][Full Text] [Related]  

  • 3. What have we learned from the large outcomes trials of COX-2 selective inhibitors? The rheumatologist's perspective.
    Hochberg MC
    Clin Exp Rheumatol; 2001; 19(6 Suppl 25):S15-22. PubMed ID: 11695246
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Current perspective on the cardiovascular effects of coxibs.
    Konstam MA; Weir MR
    Cleve Clin J Med; 2002; 69 Suppl 1():SI47-52. PubMed ID: 12086293
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New directions in symptomatic therapy for patients with osteoarthritis and rheumatoid arthritis.
    Hochberg MC
    Semin Arthritis Rheum; 2002 Dec; 32(3 Suppl 1):4-14. PubMed ID: 12528069
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gastrointestinal safety and tolerability of nonselective nonsteroidal anti-inflammatory agents and cyclooxygenase-2-selective inhibitors.
    Peura DA
    Cleve Clin J Med; 2002; 69 Suppl 1():SI31-9. PubMed ID: 12086291
    [TBL] [Abstract][Full Text] [Related]  

  • 7. COX-2-selective inhibitors in the treatment of arthritis.
    Schnitzer TJ; Hochberg MC
    Cleve Clin J Med; 2002; 69 Suppl 1():SI20-30. PubMed ID: 12086290
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Recent development of selective cyclooxygenase-2 inhibitors].
    Kawai S
    Nihon Rinsho; 2002 Dec; 60(12):2370-7. PubMed ID: 12510364
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of the cyclooxygenase-2 specific inhibitor valdecoxib versus nonsteroidal antiinflammatory agents and placebo on cardiovascular thrombotic events in patients with arthritis.
    White WB; Strand V; Roberts R; Whelton A
    Am J Ther; 2004; 11(4):244-50. PubMed ID: 15266215
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Update on clinical developments with celecoxib, a new specific COX-2 inhibitor: what can we expect?
    Geis GS
    Scand J Rheumatol Suppl; 1999; 109():31-7. PubMed ID: 10422544
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Osteoarthritis management: the role of cyclooxygenase-2-selective inhibitors.
    Schnitzer TJ
    Clin Ther; 2001 Mar; 23(3):313-326; discussion 311-2. PubMed ID: 11318071
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Outcomes studies of the gastrointestinal safety of cyclooxygenase-2 inhibitors.
    Scheiman JM
    Cleve Clin J Med; 2002; 69 Suppl 1():SI40-6. PubMed ID: 12086292
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical experience with cyclooxygenase-2 inhibitors.
    Lanas A
    Rheumatology (Oxford); 2002 Apr; 41 Supp 1():16-22; discussion 35-42. PubMed ID: 12173276
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical pharmacology of selective COX-2 inhibitors.
    Capone ML; Tacconelli S; Sciulli MG; Patrignani P
    Int J Immunopathol Pharmacol; 2003; 16(2 Suppl):49-58. PubMed ID: 14552704
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cyclooxygenase inhibition and thrombogenicity.
    Catella-Lawson F; Crofford LJ
    Am J Med; 2001 Feb; 110 Suppl 3A():28S-32S. PubMed ID: 11173047
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An introduction to aspirin, NSAIDs, and COX-2 inhibitors for the primary prevention of cardiovascular events and cancer and their potential preventive role in bladder carcinogenesis: part I.
    Moyad MA
    Semin Urol Oncol; 2001 Nov; 19(4):294-305. PubMed ID: 11769881
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An evidence-based evaluation of the gastrointestinal safety of coxibs.
    Bombardier C
    Am J Cardiol; 2002 Mar; 89(6A):3D-9D. PubMed ID: 11909555
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nonsteroidal anti-Inflammatory drugs and cardiovascular risk.
    Howard PA; Delafontaine P
    J Am Coll Cardiol; 2004 Feb; 43(4):519-25. PubMed ID: 14975457
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The gastrointestinal safety of the COX-2 selective inhibitor etoricoxib assessed by both endoscopy and analysis of upper gastrointestinal events.
    Hunt RH; Harper S; Watson DJ; Yu C; Quan H; Lee M; Evans JK; Oxenius B
    Am J Gastroenterol; 2003 Aug; 98(8):1725-33. PubMed ID: 12907325
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Developing an economic rationale for the use of selective COX-2 inhibitors for patients at risk for NSAID gastropathy.
    Fendrick AM
    Cleve Clin J Med; 2002; 69 Suppl 1():SI59-64. PubMed ID: 12086296
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.